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Endometriosis is a chronic, estrogen-dependent disease associated with infertility and pelvic pain. Endometriosis is
defined by the presence of extra-uterine endometrial tissue. It affects approximately 10% of reproductive-aged women.
However, the underlying etiology, pathogenesis and pathophysiology remain to be fully elucidated. Knowledge
of these factors is indispensable for the development of targeted therapies for prevention and treatment of
endometriosis. Several studies, including those from our laboratory, have suggested that aberrant activation of
the Wnt/β-catenin pathway may be involved in the pathophysiology of endometriosis. This is a review of the
literature focused on the aberrant activation of the Wnt/β-catenin pathway in patients with endometriosis, and
on how targeting the Wnt/targeting pathway may be a potentially effective approach for treating and/or
preventing endometriosis.
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Endometriosis is a chronic, estrogen-dependent disease
associated with infertility and pelvic pain. Endometriosis
is defined by the presence of extra-uterine endometrial
tissue. It affects approximately 10% of reproductive-aged
women [1]. However, the underlying etiology, pathogenesis
and pathophysiology remain to be fully elucidated. Know-
ledge of these factors is indispensable for the development
of targeted therapies for prevention and treatment of
endometriosis.
Several studies, including those from our laboratory,
have suggested that aberrant activation of the Wnt/β-ca-
tenin pathway may be involved in the pathophysiology
of endometriosis [2-9]. The Wnt/β-catenin pathway has
crucial roles in embryonic development, tissue self-renewal,
and various diseases [10-13]. In the absence of Wnt ligands
(“off” state), β-catenin is degraded by the APC/Axin/GSK-
3ß complex [10-13] (Figure 1A). Binding of Wnt ligands
to the Frizzled transmembrane receptors and their LRP* Correspondence: sachikoma@aol.com
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unless otherwise stated.co-receptors (“on” state) leads to the inactivation of
GSK-3ß and accumulation of β-catenin in the cytoplasm.
Then, the elevated cytosolic β-catenin can translocate
to the nucleus, where it interacts with the Tcf/LEF tran-
scription factors, leading to transcriptional activation of
Wnt-responsive genes (Figure 1B). Many Wnt-responsive
genes have crucial roles in cell proliferation, migration,
and invasion [10-13]. These processes are also common in
endometriosis [1].
This is a review of the literature focused on the aberrant
activation of the Wnt/β-catenin pathway in patients with
endometriosis, and on how targeting the Wnt/targeting
pathway may be a potentially effective approach for treat-
ing and/or preventing endometriosis.Review
Aberrant activation of the Wnt/β-catenin pathway in
endometrium of patients with endometriosis
Menstrual endometrium of patients with endometriosis
Pathogenesis of endometriosis remains unclear. However,
the implantation theory is the most widely accepted [1].
Endometriosis originates from retrograde menstruation of
endometrial tissue that passes through patent Fallopian
tubes into the peritoneal cavity. As retrograde menstruationral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain































Figure 1 The Wnt/β-catenin signaling pathway. A) In the absence of Wnt ligands such as Wnt1, Wnt3a, and Wnt8 (“off” state), β-catenin is
degraded by the APC/Axin/GSK-3ß complex. B) Binding of Wnt ligands to the Frizzled transmembrane receptors and their LRP co-receptors
(“on” state) leads to the inactivation of GSK-3ß and accumulation of β-catenin in the cytoplasm. Then, the elevated cytosolic β-catenin can translocate
to the nucleus, where it interacts with the Tcf/LEF transcription factors, leading to transcriptional activation of Wnt-responsive genes. Many
Wnt-responsive genes have crucial roles in cell proliferation, migration, and invasion. Two fungal derivatives (PKF 115–854 and CGP049090),
small-molecule antagonists of the Tcf/β-catenin complex, disrupt the critical protein-protein interaction between β-catenin and Tcf as
indicated in this figure. Effects of PKF 115–854 and/or CGP049090 on endometriosis are summarized in Table 1. APC: adenomatous polyposis
coli, GSK-3ß: glycogen synthase kinase 3β, LRP: lipoprotein receptor-related protein, TCF/LEF: T-cell factor/lymphocyte enhancer factor, CK1:
casein kinase, DVL: disheveled.
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endometriosis only occurs in about 10% of women during
their reproductive years. One possible explanation is that
the eutopic endometrial cells of women with endometriosis
may be functionally and biochemically different from those
of women without endometriosis [1].
Our previous study showed significantly higher total
and active forms of MMP-9 in the menstrual epithelial and
stromal cells of patients with endometriosis compared to
those of patients without endometriosis [4]. MMP-9 is one
of the Tcf/β-catenin target genes (www.stanford.edu/group/
nusselab/cgi-bin/wnt/target_genes). Treatment with PKF
115–584, a small-molecule antagonist of the Tcf/β-catenin
complex, decreased the amount of total MMP-9 approxi-
mately 75% in epithelial cells and 85% in stromal cells in
patients with endometriosis [4]. Furthermore, treatment
with PKF 115–584 decreased the amount of active MMP-
9 to undetectable levels in both epithelial and stromal cells
of patients with endometriosis [4]. MMP-9 activity is
known to be involved in cell invasion [14-17]. In addition,
recent studies clearly demonstrated that a latent form
of MMP-9 may play an important role in cell migration
[18,19]. Our previous study demonstrated that theinhibitory effects of cell migration and invasion of
menstrual endometrial epithelial and stromal cells of
endometriosis patients by treatment with PKF 115–584
were much higher than those of patients without endo-
metriosis [4]. These findings are consistent with those of a
previous study that demonstrated that MMP-9 secretion,
as assessed by zymography and enzyme-linked im-
munosorbent assay (ELISA), was increased in women
with endometriosis compared to healthy women [20].
According to the implantation theory, two processes
appear to be critical for the establishment of endometriosis:
migration and invasion [1,21]. These findings suggested
that aberrant activation of the Wnt/β-catenin pathway
may result in increased migration and invasion of men-
strual endometrial cells of patients with endometriosis.
Furthermore, a recent study showed that human endo-
metrial basal glandular epithelial cells expressed nuclear
SOX9, a Wnt target gene, and contained a rare subpopu-
lation of cells with nuclear β-catenin [22]. These findings
suggested that the Wnt pathway was activated in the basal
endometrium. They also showed that the embryonic stem
cell-surface marker, SSEA-1, marked the human endomet-
rial basal glandular epithelial cells. Interestingly, cells in
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nuclear SOX9, and SOX9 and SSEA-1 expression patterns
were similar to those in the matched eutopic basalis epi-
thelia [22]. These investigators speculated that the ectopic
lesions might be basalis in origin following retrograde
menstruation [22]. A growing body of evidence suggests
that endometriosis may arise from stem cells [23-27].
The Wnt signaling pathway plays an essential role in
stem cell regulation [13]. Although further studies are
required to examine the role of the Wnt/β-catenin sig-
naling in SOX9– and SSEA-1–expressing endometrial
glandular epithelial cells, these findings suggested that
manipulation of Wnt signaling for stem cell regulation
might be a novel therapeutic strategy for prevention
and treatment of endometriosis.
Mid-secretory endometrium of infertile patients with
endometriosis
Endometriosis affects approximately 25%-50% of all women
with infertility [1]. However, the underlying molecular
mechanisms of endometriosis-associated infertility remain
to be elucidated. One potential cause may be endometrial
molecular defects during the implantation window [1].
Previous findings, including those from our laboratory,
suggested that the Wnt/beta-catenin signaling pathway
might be aberrantly activated in infertile patients during
the mid-secretory phase [2,6,7]. Our previous study
demonstrated punctate membranous expression of de-
phosphorylated beta-catenin in endometrial epithelial
cells of infertile patients during the mid-secretory phase
[2]. Expression of the N-terminally dephosphorylated
form of beta-catenin has been shown to be well correlated
with Wnt activity [28]. Our previous study showed sig-
nificantly higher basal cell proliferation of endometrial
epithelial and stromal cells of patients with endometri-
osis compared to patients without endometriosis in the
mid-secretory phase [4]. In addition, mRNA expression
of Cyclin D1, a Tcf/β-catenin target gene, was significantly
higher in endometrial epithelial cells of patients with
endometriosis compared to patients without endomet-
riosis in the mid-secretory phase [4]. Expression levels
of Cyclin D1 tended to be higher in the secretory phase
stromal cells of patients with endometriosis compared
to patients without endometriosis, which is in agree-
ment with with the results of a previous study [29].
Cell proliferation and Cyclin D1 mRNA expression in
epithelial and stromal cells of patients with endometriosis
were effectively decreased by treatment with PKF 115–
584, a small-molecule antagonist of the Tcf/β-catenin
complex.
A study showed that increased E2 levels activate Wnt/β-
catenin signaling to promote endometrial cell proliferation
during the proliferative phase of menstrual cycle, whereas
during the secretory phase, progesterone levels inhibitWnt/β-catenin signaling, resulting in counterbalancing
E2-induced proliferation and enhancing differentiation
[30]. In addition, a mouse study demonstrated that
stabilization of beta-catenin in the uterus resulted in
endometrial glandular hyperplasia and lack of a decidual
response [31]. In these mice, estrogen receptor (ER)-alpha
expression was increased in the epithelium [31]. A growing
body of evidence suggests that endometrium of patients
with endometriosis has an altered response to progesterone
and persistence of the proliferative phenotype [7,29,32].
Studies have demonstrated impaired decidualization in
endometrial stromal cells and elevated endometrial
ER-alpha expression during the mid-secretory phase in
patients with endometriosis [33]. Furthermore, regulation
of cyclin D1, one of the target genes of the Wnt pathway
via activation of β-catenin, is impaired in endometrial
stromal cells of patients with endometriosis [7]. These
findings suggest that progesterone resistance might fail to
inhibit activation of Wnt/β-catenin signaling, resulting
in the persistence of the proliferative phenotype and
impaired decidualization in the endometrium of infer-
tile patients with endometriosis during the window of
implantation.
Aberrant activation of the Wnt/β-catenin pathway in
endometriosis
Cell proliferation, migration and invasion of endometriotic cells
The Wnt/beta-catenin pathway is involved in cell pro-
liferation, migration, and invasion [34], which are also
involved in the pathophysiology of endometriosis [1].
Our previous study showed that PKF 115–584, a small-
molecule antagonist of the Tcf/β-catenin complex, could
significantly decrease cell proliferation, migration and
invasion of endometrial and endometriotic epithelial
and stromal cells [4]. However, our previous findings
suggested that the Wnt/β-catenin signaling pathway
might not be essential for cell proliferation of endome-
triotic cells [4]. The inhibitory effect of treatment with
PKF 115–584 on cell proliferation in ovarian endometrio-
tic tissue was significantly lower than that of matched
eutopic endometrium of the same patients [4]. The cell
proliferation inhibitory effect of deep infiltrating endome-
triotic tissue and superficial peritoneal endometriotic
tissue tended to be lower than that of matched eutopic
endometrium of the same patients [4]. Furthermore,
we showed that in either non-treated or treated cells
with PKF 115–584, no significant difference in the
number of migrated epithelial and stromal cells was
observed between endometriotic tissue and matched
eutopic endometrium of the same patients [4]. In
addition, we observed that no significant difference in
percent inhibition of cell migration by treatment with
PKF 115–584 in either epithelial or stromal cells was noted
between endometriotic tissue and eutopic endometrium of
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pathway may not be as involved in the cell proliferation
and migration of diseased cells—endometriotic cells—than
their normal cell counterparts—endometrial cells.
In contrast, our previous study demonstrated that
endometriotic epithelial cells and stromal cells were more
invasive than those of matched eutopic endometrium of
the same patients [4]. These findings are in agreement
with the results of previous in vitro experiments studies
that showed that endometriotic cells have invasive and
metastatic phenotypes similar to metastatic carcinoma
cells [35,36]. The numbers of invasive endometriotic epi-
thelial and stromal cells were effectively decreased by
treatment with PKF 115–584 [4]. Levels of active MMP-2
in endometriotic epithelial cells and total and active
MMP-9 in endometriotic stromal cells were significantly
decreased compared to those of matched eutopic endo-
metrium following treatment with PKF 115–584 [4]. Both
MMP-9 and MMP-2 are Tcf/β-catenin target genes [4].
These findings suggested that inhibition of active MMP2
and MMP9 by treatment with PKF 115–584 decreased
the numbers of invasive endometriotic epithelial cells and
stromal cells. Aberrant activation of the Wnt/β-catenin
signaling pathway may be involved in the invasive pheno-
type of endometriotic cells.
Furthermore, a recent study demonstrated that the
activated TNFα–MMP-9-SRC-1 axis protects the ectopic
endometrium from proinflammatory cytokinemediated
apoptosis [37]. Endometriotic cells exhibit abnormal
apoptotic regulation [38]. Aberrant activation of the
Wnt/β-catenin signaling pathway might also be involved
in resistance of endometriotic stromal cells to apoptosis
through the TNFα–MMP-9 axis.
Recent studies demonstrated the presence of ectopic
endometrium in the rectovaginal septum, in the Douglas
pouch, in the rectum of human female fetuses [39,40].
They hypothesized that ectopic endometrium might be
misplaced outside the uterine cavity during the organo-
genesis [39,40]. The Wnt/beta-catenin signaling pathway
is essential for organogenesis [41]. Endometriosis in some
patients may arise from müllerian duct remnants. The
Wnt/beta-catenin signaling pathway may possibly be acti-
vated by hormonal inputs in the ectopic endometrium
after puberty starts [30,42]. However, it is unlikely that all
endometriosis could arise from müllerian duct remnants,
because the distribution of pelvic endometriosis differs
from that of embryonic duct remnants.
Fibrosis in endometriosis
Endometriosis is histologically characterized by dense fi-
brous tissue mainly composed of collagen type I [1,43].
Excess fibrosis may cause severe clinical symptoms, such
as pelvic pain, severe dysmenorrhea, and deep dyspareunia
in patients with endometriosis [44,45], Endometriosis isan estrogen-dependent disease. However, hormonal
suppressive therapy is not usually effective for deep infiltrat-
ing endometriosis [45]. Complete surgical removal of the
deep endometriotic lesions results in the best long-term re-
sults and symptomatic relief [45]. However, in addition to
the dense fibrosis, deep infiltrating endometriosis frequently
invades vital pelvic organs [45]. Surgical treatment of deep
infiltrating endometriosis should be performed by laparo-
scopic surgeons who are highly skilled and competent in
performing bowel, bladder, and ureteral surgery [45].
Despite of its clinical importance, only a few studies
have been conducted to evaluate new therapies for fibrosis
in endometriosis. The cellular and molecular mechanisms
underlying fibrosis in endometriosis remain to be fully
elucidated.
Recent studies have demonstrated the involvement of
activated Wnt/β-catenin signaling in fibrosis in several
organs [46-50]. Our previous study showed that Wnt3a
treatment in the endometrial stromal cells of patients
without endometriosis significantly increased cell pro-
liferation and migration, cell-mediated contraction of
collagen gels, and expression of fibrotic marker genes
(alpha-smooth muscle actin, type I collagen, connective
tissue growth factor, and fibronectin) [5]. We showed a
significantly lower cell-mediated collagen gel contraction
in stromal cells from patients without endometriosis com-
pared to patients with endometriosis [5]. Cell-mediated
contraction of collagen gel in stromal cells of patients
without endometriosis was increased by treatment with
Wnt3a to a level comparable with that of patients with
endometriosis [5]. Treatment with Wnt3a induced clearly
visible αSMA-positive stress fibers, the hallmark of
activated myofibroblasts, in endometrial stromal cells
of patients without endometriosis. These findings sug-
gested the involvement of the aberrant activation of the
Wnt/β-catenin pathway in the molecular and cellular
mechanisms underlying fibrogenesis of endometriosis [5].
Further studies are required whether overexpression of
Wnt3a is one of the underlying mechanisms for the devel-
opment of fibrosis in endometriosis.
Furthermore our previous study demonstrated that
mRNA expression of fibrotic marker genes was sig-
nificantly decreased by treatment with PKF 115–584
and CGP049090, small-molecule antagonists of the
Tcf/β-catenin complex [5]. Treatment with PKF 115–584
and CGP049090 significantly decreased stromal cell-
mediated contraction of collagen gels in endometrium
and endometriosis [5]. Our previous study also showed
that cell proliferation and migration of endometrial and
endometriotic stromal cells were significantly decreased
by treatment with PKF 115–584 [4]. Fibroblast migration,
proliferation, and collagen contraction are main hallmarks
of fibrogenesis [51]. Small-molecule antagonists of the
Tcf/β-catenin complex may inhibit fibrogenesis in
Matsuzaki et al. Molecular and Cellular Therapies 2014, 2:36 Page 5 of 7
http://www.molcelltherapies.com/content/2/36endometriosis [4,5]. Furthermore, we showed that treat-
ment with CGP049090 prevented the progression of fibro-
sis in a xenograft model of endometriosis in nude mice [5].
More importantly, we observed that treatment with
CGP049090 revresed established fibrosis in our mouse
model of endometriosis [5]. A study demonstrated that
treatment with ICG-001, a selective inhibitor of Wnt/β-ca-
tenin-CBP-dependent transcription, prevented and reversed
fibrosis in a mouse model of bleomycin-induced pulmonary
fibrosis [49]. These findings and our findings support that
aberrant activation of the Wnt/β-catenin signaling pathway
play an important role in the pathogenesis of fibrosis.
Chronic pelvic pain in endometriosis: potential involvement
of aberrant activation of the Wnt/β-catenin pathway
Pain is a major clinical problem in patients with endomet-
riosis [1,52-55]. However, the underlying mechanisms areTable 1 Summary of effects of small-molecule antagonists of
Model Cell type or species Inhibitor Parameters ass
In vitro assay C-EE, C-ES PKF 115-584 Cell proliferation
E-EE, E-ES CGP049090
EnE, EnS
C-EE, C-ES PKF 115-584 Cell migration
E-EE, E-ES
EnE, EnS
C-EE, C-ES PKF 115-584 Cell invasion
E-EE, E-ES
EnE, EnS




E-ES, EnS PKF 115-584 Fibrotic markers
Col-I, CTGF, andCGP049090
E-ES, EnS PKF 115-584 Collagen gel con
CGP049090
In vivo assay Mouse (female Swiss
nude mice)




C-EE: endometrial epithelial cells of patients without endometriosis, C-ES: endometr
E-EE: Endometrial epithelial cell of patients with endometriosis, E-ES: endometrial st
EnE: Endometriotic epithelial cells, EnS: endometriotic stromal cells.
MMP-2: Matrix metalloproteinase-2, MMP-9: Matrix metalloproteinase-9, αSMA: alph
CTGF: connective tissue growth factor, FN: fibronection.not yet very well understood. The group of Berkley
demonstrated in endometriosis is associated with cen-
tral sensitization that underlies pain hypersensitivity
[54]. In addition, the same group recently proposed
that painful endometriosis can be classified as a mixed
inflammatory/neuropathic pain condition [55]. Thus,
therapeutic strategies for neuropathic pain might be
applied to endometriosis [53,55]. Central sensitization-
associated synaptic plasticity in the spinal cord dorsal
horn (SCDH) critically contributes to the development
of chronic pain [52,53]. A recent study showed that both
Wnt3a and β-catenin are up-regulated in the SCDH of
various mouse pain models: the capsaicin pain model, the
HIV-gp120 pain model, and the neuropathic pain model
[56]. These results suggested that Wnt signaling pathways
are regulated by nociceptive input [56]. The activation of
Wnt signaling may contribute to the spinal cord centralthe Tcf/β-catenin complex on endometriosis
essed Functional effects Reference
C-EE, C-ES, E-EE, E-ES, EnE and EnS:
significantly inhibited vs. non-treated cells
[4]
C-EE, C-ES, E-EE, E-ES, EnE and EnS:
significantly inhibited vs. non-treated cells
[4]
C-EE, C-ES, E-EE, E-ES, EnE and EnS:




C-EE, C-ES, E-EE, E-ES, EnE and EnS:
cyclin D1, Survivin, MMP2 and MMP9
mRNA: significantly decreased vs.
non-treated cells
[4]
Total form of MMP-9 in E-EE or E-ES:
significantly decreased vs. C-EE or C-ES
Active forms of MMP-2 in EnE: significantly
decreased vs. E-EE




E-ES, EnS: αSMA, Col-I, CTGF, and FN mRNA
(with or without TGF ß1 stimulation):
significantly decreased vs. non-treated cells
[4]
EnS: percentage of αSMA-positive cells:
significantly decrased vs. non-treated cells







Staining scores for Sirius Red or Masson
Trichrome stains: significantly lower vs.
non-treated mice
[5]
ial stromal cells of patients without endometriosis.
romal cell of patients with endometriosis.
a smooth muscle actin, Col-I: Type I collagen.
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showed that nerve injury caused rapid-onset and long-
lasting expression of Wnts and activation of Wnt/Frizzled/
β-catenin signaling in primary sensory neurons, SCDH
neurons, and astrocytes [57]. Furthermore, Wnt signaling
activation stimulated production of the proinflammatory
cytokines IL-18 and TNF-α, which play an important
role in the generation of neuropathic pain, through the
β-catenin pathway in the spinal cord [57]. Blocking
Wnt/β-catenin signaling may provide a strategy for
treating neuropathic pain through IL-18 and TNF-α
inhibition [56]. Although to date no studies have inves-
tigated the activation of Wnt signaling in the SCDH in
animal models of endometriosis pain, previous animal
experiments suggested the potential involvement of
Wnt signaling activation in the molecular mechanisms
that underlie chronic pelvic pain in endometriosis.Conclusions
Studies, including those from our laboratory, suggested
that the aberrant activation of the Wnt/β-catenin path-
way may be involved in the pathophysiology of endo-
metriosis. The aberrant activation of the Wnt/β-catenin
pathway in menstrual endometrium may facilitate devel-
opment of endometriosis through increased cell migration
and invasion.
In addition, the aberrant activation of the Wnt/β-catenin
pathway may facilitate growth of endometriosis through
an increased invasive phenotype and resistance to apop-
tosis of endometriotic cells. Furthermore, the aberrant
activation of the Wnt/β-catenin pathway in mid-secretory
endometrium may result in the persistence of the prolifer-
ative phenotype and impaired decidualization in infertile
patients with endometriosis. The findings from our labora-
tory also showed the involvement of the Wnt/β-catenin sig-
naling pathway in the cellular and molecular mechanisms
underlying fibrosis in endometriosis. A small-molecule
antagonist of the Tcf/β-catenin complex prevented the
progression of fibrosis and, more importantly, reversed
established fibrosis in a xenograft model of endometriosis
in immunodeficient nude mice. These findings suggested
that targeting the Wnt signaling pathway may be a poten-
tially effective approach for treating and/or preventing
endometriosis (Table 1).
However, one major concern in targeting the Wnt/β-
catenin pathway is the potential for side effects on stem
cell maintenance and tissue homeostasis [58]. Close
attention should be paid to potential side effects of in vivo
use of the Wnt/β-catenin pathway inhibitors in patients
with endometriosis in further studies.Competing interests
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